These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37108787)

  • 41. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.
    Martin A; Xiong J; Koromila T; Ji JS; Chang S; Song YS; Miller JL; Han CY; Kostenuik P; Krum SA; Chimge NO; Gabet Y; Frenkel B
    Bone; 2015 Jun; 75():96-104. PubMed ID: 25701138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways.
    Xu H; Jia Y; Li J; Huang X; Jiang L; Xiang T; Xie Y; Yang X; Liu T; Xiang Z; Sheng J
    Biomed Pharmacother; 2022 May; 149():112902. PubMed ID: 35364377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
    Liu T; Jiang L; Xiang Z; Li J; Zhang Y; Xiang T; Wang W; Li X; Jia Y; Huang X; Lu X; Xu H; Wang X; Sheng J
    Biomed Pharmacother; 2022 Jul; 151():113140. PubMed ID: 35605290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urolithin B suppresses osteoclastogenesis via inhibiting RANKL-induced signalling pathways and attenuating ROS activities.
    Qu Z; An H; Feng M; Huang W; Wang D; Zhang Z; Yan L
    J Cell Mol Med; 2022 Aug; 26(16):4428-4439. PubMed ID: 35781786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
    Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
    J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development.
    Mukherjee A; Rotwein P
    Mol Cell Biol; 2012 Jan; 32(2):490-500. PubMed ID: 22064480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway.
    Wang N; Hao Y; Fu L
    Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function.
    Li H; Deng W; Yang J; Lin Y; Zhang S; Liang Z; Chen J; Hu M; Liu T; Mo G; Zhang Z; Wang D; Gu P; Tang Y; Yuan K; Xu L; Xu J; Zhang S; Li Y
    Biomed Pharmacother; 2024 Feb; 171():116166. PubMed ID: 38244329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Water extract of Rumex crispus prevents bone loss by inhibiting osteoclastogenesis and inducing osteoblast mineralization.
    Shim KS; Lee B; Ma JY
    BMC Complement Altern Med; 2017 Oct; 17(1):483. PubMed ID: 29070038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
    Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
    Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
    Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ASP2-1, a polysaccharide from Acorus tatarinowii Schott, inhibits osteoclastogenesis via modulation of NFATc1 and attenuates LPS-induced bone loss in mice.
    Wang J; Zhang Y; Xu X; Jin W; Jing C; Leng X; Wang M; Cao J; Wang HB; Sun L
    Int J Biol Macromol; 2020 Dec; 165(Pt B):2219-2230. PubMed ID: 33132123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling.
    Xiao Y; Li K; Wang Z; Fu F; Shao S; Song F; Zhao J; Chen W; Liu Q; Xu J
    J Cell Physiol; 2019 Aug; 234(8):13959-13968. PubMed ID: 30633330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.